| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.2 | 0.1 |
| Net income | -2.2 | -2.8 |
| EPS (diluted, $ a share) | $-1.03 | $-19.05 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +128.9% |
|---|
10-Q filed with the SEC, NASDAQ: ISPC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
iSpecimen Inc.: key numbers
- Share price
- $0.6049Close, Nov 16
- Market cap
- $1.52M
- Shares outstanding
- 2.52MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from iSpecimen Inc.
All →iSpecimen Capital Raise
iSpecimen Inc. entered into a securities purchase agreement with accredited investors for a private placement of 500 shares of Series D Convertible Preferred Stock at $800 per share. The offering generated gross proceeds of $400,000, which the company intends to use for working capital and general corporate purposes. E.F. Hutton & Co. served as the exclusive placement agent for the transaction.
- Counterparty
- E.F. Hutton & Co.
iSpecimen Signs $4.5M M&A Deal with Foldlab AI Ltd.
iSpecimen Inc. completed the acquisition of AI software assets from Foldlab AI Ltd. for an aggregate purchase price of $4.5 million, consisting of $750,000 in cash, $1.25 million in milestone payments, and $2.5 million in common stock. The acquired assets include a Disease-Associated Protein Discovery AI Agent and a Disease Trend Prediction and Monitoring AI Model, marking the company's entry into AI-powered drug discovery.
- Value
- $4.5M
- Counterparty
- Foldlab AI Ltd.
iSpecimen Reverse Stock Split
iSpecimen Inc. stockholders approved an amendment to the company's Certificate of Incorporation to effect a reverse stock split. The approved ratio range is between 1-for-10 and 1-for-100, with the final ratio to be determined by the Board of Directors.
iSpecimen M&A Deal with Foldlab AI Ltd.
iSpecimen Inc. stockholders approved the acquisition of assets from Foldlab AI Ltd., which includes the issuance of common stock as partial consideration. The company also received approval for potential future equity issuances exceeding 19.99% of outstanding shares under Nasdaq rules, while the vote on a proposed reverse stock split was adjourned to October 30, 2026.
- Counterparty
- Foldlab AI Ltd.